Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	APOB	Synonyms	FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48	Type of gene	protein-coding
Chromosome	2	Map location	2p24.1	dbXrefs
Gene perturbation-related omics dataset	PertOrg
Description	apolipoprotein B

GTO ID	GTC1340
Trial ID	NCT01061814
Disease	Familial Hypercholesterolemia
Altered gene	APOB
Therapeutic/Target gene	Target gene
Therapy	ASO
Treatment	ISIS 301012\|mipomersen sodium\|Kynamro
Location approved	US, Mexico, Argentina, South Korea
Phase	Phase1
Recruitment status	Completed
Title	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Relative Bioavailability, Pharmacokinetics, Safety, and Tolerability of Daily, Thrice Weekly, and Weekly Dosing Regimens of Mipomersen Administered Subcutaneously to Healthy Volunteers
Year	2010
Country	Canada
Company sponsor	Kastle Therapeutics, LLC
Other ID(s)	MIPO3200309

Vector information

Vector	No vector was used

Clinical Result

Cohort1: mipomersen_dose level 1

Administration route	subcutaneous injection
Dosage	mipomersen, 30 mg QD (Day 1 to 21; 630 mg total)
Pts	21
Age	Adult, Older_Adult
References	PMID: 24627419

Cohort2: mipomersen_dose level 2

Administration route	subcutaneous injection
Dosage	mipomersen, 70 mg TIW (Day 1, 3, 5, 8, 10, 12, 15, 17, and 19; 630 mg total)
Pts	21
Age	Adult, Older_Adult
References	PMID: 24627419

Cohort3: mipomersen_dose level 3

Administration route	subcutaneous injection
Dosage	mipomersen, 200 mg QW (Day 1, 8, and 15; 600 mg total)
Pts	21
Age	Adult, Older_Adult
References	PMID: 24627419

Cohort4: Placebo

Administration route	subcutaneous injection
Pts	21
Age	Adult, Older_Adult
References	PMID: 24627419

Relationship Graph

Overview of Knowledge Graph